Industries - Antifungal Drugs Market Analysis by Drug Type (Azoles, Allylamines, Echinocandins, Polyenes), by Therapeutic Indications (Aspergillosis, Dermatophytosis, Candidiasis), and by Region – Forecast to 2025

Ablation Technology Market Analysis

Antifungal Drugs Market Analysis by Drug Type (Azoles, Allylamines, Echinocandins, Polyenes), by Therapeutic Indications (Aspergillosis, Dermatophytosis, Candidiasis), and by Region – Forecast to 2025
October 2020

SKU: N/A Category:
Clear
  • Description
  • Additional information
  • Enquire about

Description

Antifungal Drugs Market Analysis by Drug Type (Azoles, Allylamines, Echinocandins, Polyenes), by Therapeutic Indications (Aspergillosis, Dermatophytosis, Candidiasis), and by Region - Forecast to 2025

Published: October 2020 | Historical Data: 2017-2019 | Base Year: 2019
SKU: ICI-HC-1017 | Number of Pages: 154 | Category: Pharmaceuticals

The global antifungal drugs market size was estimated to be USD 12.30 billion in 2019 and is expected to witness a CAGR of 4.0% during the forecast period. Major factors responsible for the growth of this market are increase in hospital-acquired infections; rising awareness about fungal infections on the skin, mouth, eye & vagina; easy access of over-the-counter drugs, and public-private partnership in the pharmaceutical industry. However, factors such as increasing approvals for generic drugs, patent expiration of innovator drugs, and rising counterfeit drugs are responsible for restraining the market growth.

Antifungal Drugs Market

By Drug Type

Based on drug type, the market is segmented into azoles, echinocandins, allylamines, and polyenes. In 2019, the azoles antifungal drug class held the dominant position in the market with leading therapeutics drugs such as Noxafil, Cresemba, Vfend, and Diflucan. Triazoles have a wide range of applications in the treatment of superficial and systemic fungal infections. However, echinocandins, allylamines, and polyenes are expected to show lucrative growth over the forecast period. This can be attributed to rising in the number of dermatological infections.

By Therapeutic Indication

Based on therapeutic indication, the market is categorized into aspergillosis, dermatophytosis, and candidiasis. In 2019, dermatophytosis segment accounted for the highest revenue share due to increasing skin infection cases. Candidiasis is a most common blood stream fungal infection caused by yeast and it is expected to show fastest CAGR over the forecast period.

Regional Insights

In 2019, North America held a dominant position in terms of revenue and is anticipated to hold its dominance over the forecast period. This is attributed to rising prevalence of infectious diseases and hospital-acquired infections. Major market players in the North American region are increasing their efforts on R&D investment and focussing on clinical trials for novel innovative drug developments. Asia Pacific is projected to show highest CAGR over the forecast period due to presence of a large populations base, availability of antifungal drugs, and high unmet clinical needs.

North America Antifungal Drugs Market Size (2017-2025), USD Billion

North America Antifungal Drugs Market

Competitor Insights

Some of the key players in the Antifungal Drugs Market are Pfizer (U.S.), Merck & Co. (U.S.), GlaxoSmithKline (UK), Astellas Pharma (Japan), Bayer (Germany), Sanofi (France), Novartis (Switzerland), Gilead Sciences (U.S.), Abbott Laboratories (U.S.), and Scynexis (U.S.). The major players operating in the antifungal drug market are adopting growth strategies such as new product development, and mergers & acquisitions to increase their global market reach.

 

This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2017 to 2025. The Antifungal Drugs Market report is categorized into the following segments and subsegments:

Antifungal Drugs Market, By Drug Type (Revenue, 2017-2025, USD Billion)

  • Azoles
    • Triazoles
      • Fluconazole
      • Itraconazole
      • Voriconazole
      • Posaconazole
      • Isavuconazole
    • Imidazoles
      • Ketoconazole
  • Echinocandins
    • Micafungin (Mycamine)
    • Caspofungin ( Cancidas)
    • Anidulafungin (Eraxis)
  • Allylamines
    • Naftifine
    • Terbinafine
  • Polyenes
    • Amphotericin
    • Nystatin
    • Candicidin

Antifungal Drugs Market, By Therapeutic Indication (Revenue, 2017-2025, USD Billion)

  • Aspergillosis
  • Dermatophytosis
  • Candidiasis
  • Oral
  • Vaginal
  • Vulvovaginal (VVC)
  • Esophageal

Antifungal Drugs Market, By Region (Revenue, 2017-2025, USD Billion)

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of LATAM
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Scope of Antifungal Drugs Market Report:

Key Parameters Details
Data Availability 2017-2025
Historical Years 2017-2019
Base Year Considered 2019
Forecast Period 2020-2025
Company Profiles 10
Companies Considered (Across Value Chain) >80
Value Units Value in USD and CAGR in %
Market Segments Drug type, Therapeutic Indications, and Region
Regional Coverage North America (U.S. and Canada), Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe), Asia Pacific (China, Japan, Australia, India, South Korea, Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, Rest of LATAM), and the Middle East & Africa (South Africa, Saudi Arabia, Rest of MEA)
Key Market Players Pfizer (U.S.), Merck & Co. (U.S.), GlaxoSmithKline (UK), Astellas Pharma (Japan), Bayer (Germany), Sanofi (France), Novartis Switzerland, Gilead Sciences (U.S.), Abbott Laboratories (U.S.), Scynexis (U.S.).
Custom Analysis Customization up to 60 analyst hours

Antifungal Drugs Market, By Drug Type (Revenue, 2017-2025, USD Billion)

  • Azoles
    • Triazoles
      • Fluconazole
      • Itraconazole
      • Voriconazole
      • Posaconazole
      • Isavuconazole
    • Imidazoles
      • Ketoconazole
  • Echinocandins
    • Micafungin (Mycamine)
    • Caspofungin ( Cancidas)
    • Anidulafungin (Eraxis)
  • Allylamines
    • Naftifine
    • Terbinafine
  • Polyenes
    • Amphotericin
    • Nystatin
    • Candicidin

Antifungal Drugs Market, By Therapeutic Indication (Revenue, 2017-2025, USD Billion)

  • Aspergillosis
  • Dermatophytosis
  • Candidiasis
  • Oral
  • Vaginal
  • Vulvovaginal (VVC)
  • Esophageal

Antifungal Drugs Market, By Region (Revenue, 2017-2025, USD Billion)

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of LATAM
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of MEA
1. Research Methodology
 1.1. Research Objective
 1.2. Study Scope: Market Segments
 1.3. Study Timeframe, Limitations & Currency
 1.4. Domain-Assisted Cognition (DAC) Framework
  1.4.1. Three-stage Research Methodology
   1.4.1.1. Understand Ecosystem
    1.4.1.1.1. Secondary Research
    1.4.1.1.2. Primary Research
    1.4.1.1.3. Internal Repository
   1.4.1.2. Synthesize Information
    1.4.1.2.1. Data Analysis
    1.4.1.2.2. Data Triangulation
   1.4.1.3. Predict/Project Growth
    1.4.1.3.1. Market Size Estimation
     1.4.1.3.1.1. Bottom-up Approach
     1.4.1.3.1.2. Top-down Approach
    1.4.1.3.2. Data Validation
  1.4.2. Two-stage Quality Check Mechanism
   1.4.2.1. Inspection & Reporting
   1.4.2.2. Quality Audit
2. Market Summary
 2.1. Market Definition & Market Landscape
 2.2. Market Segment Snapshot
 2.3. Geographic Market Snapshot
3. Market Dynamics
 3.1. Market Driver Analysis
  3.1.1. Increasing prevalence of fungal infections
  3.1.2. Growing awareness of fungal diseases
  3.1.3. Rising R&D for innovative drug development
  3.1.4. New product launches
 3.2. Market Restraint Analysis
  3.2.1. Increasing drugs counterfeit
  3.2.2. Growing generic drugs competition
 3.3. Market Opportunities
  3.3.1. Market opportunities in emerging economies
  3.3.2. Increasing public-private partnership in pharmaceuticals industry
4. Industry Outlook
 4.1. Key Market Trends
 4.2. Value Chain Analysis
 4.3. Porter’s 5 Forces Analysis
 4.4. Pricing Analysis (2017-2019)
 4.5. Product Benchmarking
5. Covid-19 Impact and Deviation Analysis
 5.1. Covid-19 Prevalence Analysis
 5.2. Key Market Trends
 5.3. Market Size Deviation Analysis (2020-2025)
6. Antifungal Drugs Market Size and Forecast, by Drug Type (2017-2025), USD Billion
 6.1. Azoles
 6.2. Triazoles
  6.2.1. Fluconazole
  6.2.2. Itraconazole
  6.2.3. Voriconazole
  6.2.4. Posaconazole
  6.2.5. Isavuconazole
 6.3. Imidazoles
  6.3.1. Ketoconazole
  6.3.2. Echinocandins
  6.3.3. Micafungin (Mycamine)
  6.3.4. Caspofungin (Cancidas)
  6.3.5. Anidulafungin (Eraxis)
 6.4. Allylamines
  6.4.1. Naftifine
  6.4.2. Terbinafine
 6.5. Polyenes
  6.5.1. Amphotericin
  6.5.2. Nystatin
  6.5.3. Candicidin
7. Antifungal Drugs Market Size and Forecast, by Therapeutic Indication (2017-2025), USD Billion
 7.1. Aspergillosis
 7.2. Dermatophytosis
 7.3. Candidiasis
  7.3.1. Oral
  7.3.2. Vaginal
  7.3.3. Vulvovaginal (VVC)
  7.3.4. Esophageal
8. Antifungal Drugs Market, Regional Analysis (2017-2025), USD Billion
 8.1. North America
  8.1.1. Introduction
   8.1.1.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
    8.1.1.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
   8.1.1.3. Market Size & Forecast, by Country (2017-2025), USD Billion
  8.1.2. U.S.
   8.1.2.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.1.2.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
  8.1.3. Canada
   8.1.3.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.1.3.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
 8.2. Europe
  8.2.1. Introduction
   8.2.1.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.2.1.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
   8.2.1.3. Market Size & Forecast, by Country (2017-2025), USD Billion
  8.2.2. Germany
   8.2.2.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.2.2.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
  8.2.3. UK
   8.2.3.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.2.3.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
  8.2.4. France
   8.2.4.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.2.4.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
  8.2.5. Spain
   8.2.5.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.2.5.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
  8.2.6. Italy
   8.2.6.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.2.6.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
  8.2.7. Russia
   8.2.7.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.2.7.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
  8.2.8. Rest of Europe
   8.2.8.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.2.8.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
 8.3. Asia Pacific (APAC)
  8.3.1. Introduction
   8.3.1.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.3.1.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
   8.3.1.3. Market Size & Forecast, by Country (2017-2025), USD Billion
  8.3.2. China
   8.3.2.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.3.2.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
  8.3.3. Japan
   8.3.3.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.3.3.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
  8.3.4. India
   8.3.4.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.3.4.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
  8.3.5. Australia
   8.3.5.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.3.5.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
  8.3.6. South Korea
   8.3.6.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.3.6.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
  8.3.7. Rest of Asia Pacific
   8.3.7.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.3.7.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
 8.4. Latin America (LATAM)
  8.4.1. Introduction
   8.4.1.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.4.1.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
   8.4.1.3. Market Size & Forecast, by Country (2017-2025), USD Billion
  8.4.2. Brazil
   8.4.2.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.4.2.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
  8.4.3. Mexico
   8.4.3.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.4.3.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
  8.4.4. Argentina
   8.4.4.1. Market Size & Forecast, by Type (2017-2025), USD Billion
   8.4.4.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
  8.4.5. Rest of LATAM
   8.4.5.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.4.5.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
 8.5. Middle East & Africa (MEA)
  8.5.1. Introduction
   8.5.1.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.5.1.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
   8.5.1.3. Market Size & Forecast, by Country (2017-2025), USD Billion
  8.5.2. South Africa
   8.5.2.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.5.2.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
  8.5.3. Saudi Arabia
   8.5.3.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.5.3.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
  8.5.4. Rest of MEA
   8.5.4.1. Market Size & Forecast, by Drug Type (2017-2025), USD Billion
   8.5.4.2. Market Size & Forecast, by Therapeutic Indication (2017-2025), USD Billion
9. Competitor Analysis
 9.1. Market Player Comparison
 9.2. Product-wise Player Mapping
 9.3. Region-wise Player Mapping
 9.4. Market Share Analysis
 9.5. Market Position Analysis
 9.6. Recent Development Analysis
10. Company Profiles
 10.1. Pfizer (U.S.)
  10.1.1. Company Overview
  10.1.2. Company Financials
  10.1.3. Product Portfolio
  10.1.4. Recent Developments
 10.2. Merck & Co. (U.S.)
  10.2.1. Company Overview
  10.2.2. Company Financials
  10.2.3. Product Portfolio
  10.2.4. Recent Developments
 10.3. GlaxoSmithKline (UK)
  10.3.1. Company Overview
  10.3.2. Company Financials
  10.3.3. Product Portfolio
  10.3.4. Recent Developments
 10.4. Astellas Pharma (Japan)
  10.4.1. Company Overview
  10.4.2. Company Financials
  10.4.3. Product Portfolio
  10.4.4. Recent Developments
 10.5. Bayer (Germany)
  10.5.1. Company Overview
  10.5.2. Company Financials
  10.5.3. Product Portfolio
  10.5.4. Recent Developments
 10.6. Sanofi (France)
  10.6.1. Company Overview
  10.6.2. Company Financials
  10.6.3. Product Portfolio
  10.6.4. Recent Developments
 10.7. Novartis(Switzerland)
  10.7.1. Company Overview
  10.7.2. Company Financials
  10.7.3. Product Portfolio
  10.7.4. Recent Developments
 10.8. Novartis(Switzerland)
  10.8.1. Company Overview
  10.8.2. Company Financials
  10.8.3. Product Portfolio
  10.8.4. Recent Developments
 10.9. Abbott Laboratories (U.S.)
  10.9.1. Company Overview
  10.9.2. Company Financials
  10.9.3. Product Portfolio
  10.9.4. Recent Developments
 10.10. Abbott Laboratories (U.S.)
  10.10.1. Company Overview
  10.10.2. Company Financials
  10.10.3. Product Portfolio
  10.10.4. Recent Developments

Key questions addressed by the research report-

  1. What are the current market trends and future market forecast from 2019 to 2025 for Antifungal Drugs market?
  2. What are the market dynamics and probable opportunities for market players during the forecast period?
  3. Initiatives undertaken my market players to address the COVID-19 impact to sustain in the competitive market.
  4. Which geographies have immense opportunities in different segments of the Antifungal Drugs market?
  5. What are the recent strategies adopted by market players such as product launch, partnership, agreement, collaboration, merger & acquisition, and geographical expansion?


    Have any question? Check your free sample before purchase or connect with our expert.

    Additional information

    Licensing Types

    , , ,

    Enquire about Antifungal Drugs Market Analysis by Drug Type (Azoles, Allylamines, Echinocandins, Polyenes), by Therapeutic Indications (Aspergillosis, Dermatophytosis, Candidiasis), and by Region - Forecast to 2025